Search CommunityWalk:


CytImmune Sciences, Inc.

9640 Medical Center Drive
Rockville, MD 20850, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

CytImmune Sciences, Inc. is a nano-medicine company focused on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. It was established in 1988 by Lawrence Tamarkin and Giulio F. Paciotti with a goal to mitigate the risks of drug development and build from these core technologies families of first-in-class therapeutics with accelerated clinical timelines, new commercialization value, and ultimately achieving greater patient benefits.

CytImmune's tumor-targeting technology platform offers the potential to enable and/or expand the clinical benefit of a variety of toxic agents (such as tumor necrosis factor alpha (TNF), interleukins and interferons, monoclonal antibodies, chemotherapeutic agents, etc) which may be used to treat multiple types of solid tumors -- either as monotherapies or in combination with existing standards of care. Colloidal Gold masks the Polyethylene glycol (PEG) masks particles from immune recognition preventing uptake by liver and spleen and the nanoparticles exit circulatory system only at the tumor neovasculature due to leakiness of blood vessels. The TNF targeting molecule on particle's surface binds to receptors causing vascular disruption in and around tumor sites. Its tumor-targeted delivery can be ascribed to the size and composition of the nanoparticles regardless of tumor type.

CytImmune has developed a method to generate fully human monoclonal antibodies (mAbs) using lymphocytes from normal donors. The technology uses the properties of gold nanoparticles to create an "antigen presentation" system, which loosely mimics the natural presentation of antigens by cells. Its human drug candidates include: CYT-6091, (Aurimune) Pegylated Colloidal Gold bound TNF; CYT-21001, (AuriTol) Pegylated Colloidal Gold bound TNF with Paclitaxel; CYT-31000, (AuriCin) Pegylated Colloidal Gold bound TNF with Doxorubicin; CYT-41000, Pegylated Colloidal Gold bound TNF with Interleukin-12; etc.

CytImmune has partnerships with University of Maryland Biotechnology Institute, Boehringer Ingelheim, EntreMed Inc, National Institutes of Health, The US Department of Health & Human Services and OctoPlus N.V.